As­traZeneca makes $1B-plus in cash-and-stock deal grant­i­ng So­bi US rights to RSV drug Synagis

As­traZeneca $AZN has di­vest­ed the US rights to its pre­ven­ta­tive RSV drug, Synagis, to Swedish Or­phan Biovit­rum AB (So­bi) for $1.5 bil­lion in cash …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.